Olatec Therapeutics

Olatec Therapeutics company information, Employees & Contact Information

Olatec is a Phase 2 clinical stage biotech company at the forefront of an emerging class of innovative, oral inflammation therapeutics. The Company’s lead drug candidate, dapansutrile, is a proprietary specific NLRP3 inhibitor. The Company has advanced dapansutrile from discovery to its current later-stage clinical development in arthritis, diabetes, neuroinflammatory diseases and cancer. Dapansutrile is positioned to become a breakthrough treatment with early human data showing its potential to safely modulate the body’s immune system allowing for the restoration of immune balance, a necessary step to treat or prevent disease progression and prognosis in patients. Olatec’s preclinical and clinical studies have been published in top medical and scientific journals. On the strength of dapansutrile’s benign safety profile and robust clinical data, Olatec’s clinical trials are now being conducted in well-known international centers of excellence. With a mission to translate scientific potential into medical practice and become best-in-class in treating chronic inflammation that drives disease progression with a cost-effective and patient-friendly (orally dosed) therapeutic. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands.

Company Details

Employees
15
Founded
-
Address
New York, New York 10065, Us
Phone
833-652-8321
Email
in****@****tec.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
olatec.com
Keywords
LLC.
HQ
New York, New York
Looking for a particular Olatec Therapeutics employee's phone or email?

Olatec Therapeutics Questions

News

Andy Cunningham Joins Olatec Therapeutics Board of Directors - PR Newswire

Andy Cunningham Joins Olatec Therapeutics Board of Directors PR Newswire

Marc Y. Donath MD Appointed to Olatec’s Clinical Advisory Board - citybiz

Marc Y. Donath MD Appointed to Olatec’s Clinical Advisory Board citybiz

Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson’s Disease with its NLRP3 Inhibitor, Dapansutrile - Business Wire

Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson’s Disease with its NLRP3 Inhibitor, Dapansutrile Business Wire

Olatec initiates dapansutrile Phase II diabetes trial - Clinical Trials Arena

Olatec initiates dapansutrile Phase II diabetes trial Clinical Trials Arena

First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec's NLRP3 Inhibitor, Dapansutrile - PR Newswire

First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec's NLRP3 Inhibitor, Dapansutrile PR Newswire

Olatec Therapeutics Announces the Final Closing, Led by Sanders Morris Harris, on Its $40 Million Series A Financing Round - Business Wire

Olatec Therapeutics Announces the Final Closing, Led by Sanders Morris Harris, on Its $40 Million Series A Financing Round Business Wire

Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed - Cure Parkinson's

Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed Cure Parkinson's

Craig T. Basson, MD, PhD Joins Olatec Therapeutics Board of Directors - citybiz

Craig T. Basson, MD, PhD Joins Olatec Therapeutics Board of Directors citybiz

Olatec to launch Phase II trial of dapansutrile for Parkinson’s disease - Clinical Trials Arena

Olatec to launch Phase II trial of dapansutrile for Parkinson’s disease Clinical Trials Arena

The NLRP3 inflammasome inhibitor, OLT1177®, ameliorates experimental allergic asthma in mice - Wiley Online Library

The NLRP3 inflammasome inhibitor, OLT1177®, ameliorates experimental allergic asthma in mice Wiley Online Library

Biotech company partners with National Jewish Health to test potential Covid-19 therapy - The Business Journals

Biotech company partners with National Jewish Health to test potential Covid-19 therapy The Business Journals

Breaking the Cycle of Inflammation in Parkinson’s Disease - BioSpace

Breaking the Cycle of Inflammation in Parkinson’s Disease BioSpace

Many US rheumatologists fail to follow ACR gout guidelines for urate lowering drug dosage - Healio

Many US rheumatologists fail to follow ACR gout guidelines for urate lowering drug dosage Healio

Cytokine Release Syndrome Pipeline Assessment Report 2025: Emerging Therapeutics and Market Opportunities Revealed | DelveInsight - The Globe and Mail

Cytokine Release Syndrome Pipeline Assessment Report 2025: Emerging Therapeutics and Market Opportunities Revealed | DelveInsight The Globe and Mail

Press Release: Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed - Cure Parkinson's

Press Release: Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed Cure Parkinson's

Mustafa Noor, MD, FACP, Joins Olatec as Chief Medical Officer - citybiz

Mustafa Noor, MD, FACP, Joins Olatec as Chief Medical Officer citybiz

Top Olatec Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant